TB-500 (Thymosin Beta-4 Fragment) – Comprehensive Research Overview (2026)
TB-500, also known as Thymosin Beta-4 fragment (Ac-LKKTETQ), is a synthetic heptapeptide derived from the naturally occurring 43-amino-acid protein Thymosin Beta-4. It is primarily researched for its ability to regulate actin dynamics, promote cell migration, angiogenesis, and tissue remodeling. TB-500 is one of the most studied regenerative peptides and is frequently used in research for musculoskeletal injuries, wound healing, and recovery protocols. It is commonly stacked with BPC-157 for synergistic effects.
→ View TB-500 (for laboratory research use only)
Chemical Structure and Properties
- Amino Acid Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ)
- Molecular Weight: ≈889 Da
- Form: Lyophilized powder for subcutaneous injection
- Key Feature: N-terminal acetylation enhances stability; represents the active actin-binding domain of full Thymosin Beta-4
Mechanism of Action
TB-500 regulates actin polymerization by sequestering G-actin, maintaining a cellular reservoir for rapid F-actin assembly when needed. This promotes:
- Cell migration and chemotaxis of fibroblasts, keratinocytes, and progenitor cells
- Angiogenesis via upregulation of VEGF
- Extracellular matrix remodeling and reduced scar formation
- Anti-inflammatory and anti-fibrotic effects
It provides more systemic cytoskeletal support compared to the localized cytoprotective actions of BPC-157.
Clinical Evidence and Research Findings
Extensive preclinical data in rodent, rabbit, and equine models demonstrate accelerated healing in tendon, ligament, muscle, wound, and cardiac injury models. Human evidence is more limited and primarily extrapolated from full-length Thymosin Beta-4 studies. Anecdotal and clinical reports in wellness and sports medicine frequently highlight faster recovery from soft-tissue injuries when TB-500 is used, often in combination with BPC-157. No large Phase 3 trials exist for musculoskeletal indications.
→ Interested in researching TB-500? View Product Options
Benefits (Research & Clinical Observations)
- Accelerated tendon, ligament, and muscle repair
- Enhanced wound healing and reduced scar formation
- Improved flexibility and reduced inflammation
- Support for cardiovascular and ocular tissue repair
- Synergistic effects when stacked with BPC-157
Typical Dosing Protocols (Off-Label / Compounded)
- Common protocols: 2–7.5 mg per week (often split into 2 doses during loading phase, then 2–4 mg/week maintenance)
- Loading phase: Higher frequency (e.g., 4–8 mg split over first 1–2 weeks)
- Cycles: 4–12 weeks depending on injury severity
- Routes: Subcutaneous (systemic) or local injection near injury site
Safety Profile and Side Effects
TB-500 has shown a favorable short-term safety profile in available studies.
Common side effects:
- Mild injection-site reactions
- Transient fatigue or headaches (rare)
Monitoring recommended: Standard labs for individuals with pre-existing conditions. Long-term human safety data are limited. Contraindicated in active cancer.
TB-500 vs BPC-157 vs GHK-Cu – Quick Comparison
| Aspect | TB-500 | BPC-157 | GHK-Cu |
|---|---|---|---|
| Primary Focus | Cell migration & actin | Localized cytoprotection | Collagen & skin repair |
| Best For | Systemic soft tissue | Tendons, gut, wounds | Skin rejuvenation |
| Administration | Injectable | Oral or injectable | Topical or injectable |
| FDA Status | Not approved | Not approved | Not approved |
FAQ – Frequently Asked Questions
What is the difference between TB-500 and BPC-157? TB-500 excels at systemic cell migration and remodeling, while BPC-157 focuses on localized cytoprotection and vascular repair. They are often stacked for enhanced results.
Can TB-500 be used alone? Yes, but most research protocols combine it with BPC-157 for synergistic healing.
How long until results are seen? Many users report reduced pain and improved mobility within 1–3 weeks, with full tissue benefits accumulating over 4–8 weeks.
Is TB-500 FDA approved? No. It is available only as a research chemical or through compounding pharmacies under physician supervision.
Can TB-500 be taken orally? No. It is typically administered by subcutaneous injection.
Summary
TB-500 is a Thymosin Beta-4 fragment researched for its ability to regulate actin, promote cell migration, angiogenesis, and tissue remodeling. It is one of the most popular regenerative peptides, especially when combined with BPC-157 for musculoskeletal and soft-tissue recovery. While preclinical data are compelling, human clinical evidence remains limited. As with all compounds in this library, TB-500 is not an approved drug and should only be considered under qualified medical supervision with appropriate monitoring.
For Laboratory Research Use View TB-500 →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.